Mankind Pharma has announced that its Board of Directors will convene on November 6, 2025, to review and approve the unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025 (Q2 FY26). The company has also kept its trading window closed and it will remain closed until November 8, 2025.
Board Meeting Announcement
The Board of Directors of Mankind Pharma is scheduled to meet on November 6, 2025, to discuss and approve the company’s financial performance.
Financial Results Review
During the meeting, the board will consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025 (Q2 FY26). This announcement confirms the company’s commitment to timely financial reporting and corporate governance.
Trading Window Closure
As previously announced on September 25, 2025, the trading window for the company’s securities remains closed. It will remain closed until November 8, 2025.
Source: BSE